Clinically significant drug interactions

American Family Physician

Volumn 61, Issue 6, 2000, Pages 1745-1754

  Ament, Paul W ^a   Bertolino, John G ^a   Liszewski, James L ^a  

^a Latrobe Area Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CIMETIDINE; CIPROFLOXACIN; CISAPRIDE; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LITHIUM; METRONIDAZOLE; NEFAZODONE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PHENYTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RITONAVIR; SILDENAFIL; SUCRALFATE; TROGLITAZONE; UNINDEXED DRUG; WARFARIN;

DRUG ABSORPTION; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG METABOLISM; HUMAN; POLYPHARMACY; PRIMARY MEDICAL CARE; REVIEW;

DRUG ANTAGONISM; DRUG INTERACTIONS; DRUG SYNERGISM; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 0034653710     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Weibert RT, Lorentz SM, Townsend RJ, Cook CE, Klauber MR, Jagger PI. Effect of erythromycin in patients receiving long-term warfarin therapy. Clin Pharm 1989;8:210-4.
2. Wells PS, Holbrook AM, Crowther NR, Hirsch J. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121:576-83.
3. Hansten PD, Horn JR. Hansten and Horn's Drug interactions analysis and management. Vancouver, Wash.: Applied Therapeutics, 1997;7-8,309,368-9,415-6.
4. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657-62.
5. Bell WR. Acetaminophen and warfarin: undesirable synergy [Editorial]. JAMA 1998;279:702-3.
6. Chan TY. Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance. Ann Pharmacother 1995;29:1274-83.
7. Turpie AG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, et al. A comparison of aspirin with placebo in patients treated with warfarin after heartvalve replacement. N Engl J Med 1993;329:524-9.
8. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998;351:233-41.
9. Kaplan-Machlis B, Klostermeyer BS. The cyclooxygenase-2 inhibitors: safety and effectiveness, Ann Pharmacother 1999;33:979-88.
10. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665-70.
11. Lomaestro BM, Bailie GR. Quinolone-cation interactions: a review. Drug Intell Clin Pharm 1991:25: 1249-58.
12. Anastasio GD, Cornell KO, Menscer DM. Drug interactions: keeping it straight. Am Fam Physician 1997;56:883-8,891-4 [Published errata in Am Fam Physician 1997;56:1728-9 and 1997;56:2192].
13. Ament PW, Paterson A. Drug interactions with the nonsedating antihistamines. Am Fam Physician 1997;56:223-31.
14. Wagner JC. Rifampin-phenytoin drug interaction. Drug Intell Clin Pharm 1984;18:497.
15. Helms SE, Bredle DL, Zajic J, Jarjoura D, Brodell RT, Krishnarao I. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol 1997;36(5 pt 1): 705-10.
16. Fleischer AB Jr, Resnick SD. The effect of antibiotics on the efficacy of oral contraceptives. A controversy revisited. Arch Dermatol 1989;125:1562-4.
17. Physicians' desk reference. 53rd ed. Montvale, N.J.: Medical Economics, 1999.
18. Sildenafil: an oral drug for impotence. Med Lett Drugs Ther 1998;40:51-2.
19. Kirk JK, Dupuis RE. Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient. Ann Pharmacother 1995;29:879-91.
20. Kirk JK, Lightfoot SM, Conner SL. Some clinically important drug interactions. Pharm Times 1998;(July):79-91.
21. Reaven P, Witzum JL. Lovastatin, nicotinic acid, and rhabdomyolysis [Letter]. Ann Intern Med 1988; 109:597-8.
22. Ahmad S. Lovastatin. Warfarin interaction. Arch Intern Med 1990;150:2407.
23. Vanderhoff BT, Miller KE. Major depression: assessing the role of new antidepressants. Am Fam Physician 1997;55:249-54,259-60.
24. Preskorn SH, Beber JH, Faul JC, Hirschfeld RM. Serious adverse effects of combining fluoxetine and tricyclic antidepressants [Letter]. Am J Psychiatry 1990;147:532.
25. Suchowersky O, deVries JD. Interaction of fluoxetine and selegiline [Letter]. Can J Psychiatry 1990; 35:571-2.
26. Feighner JP, Boyer WF, Tyler DL, Neborsky RJ. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990;51:222-5.
27. Mason BJ, Blackburn KH. Possible serotonin syndrome associated with tramadol and sertraline coadministration. Ann Pharmacother 1997;31: 175-7.
28. Gordon JB. SSRIs and St. John's wort: possible toxicity? [Letter] Am Fam Physician 1988;57:950,953.
29. Joffe RT, Sokolov ST. Co-administration of fluoxetine and sumatriptan: the Canadian experience. Acta Psychiatr Scand 1997;95:551-2.
30. Gardner DM, Lynd LD. Sumatriptan contraindications and the serotonin syndrome. Ann Pharmacother 1998;32:33-8.
31. Blier P, Bergeron R. The safety of concomitant use of sumatriptan and antidepressant treatments. J Clin Psychopharmacol 1995;15:106-9.
32. New "triptans" and other drugs for migraine. Med Lett Drugs Ther 1998;40:97-100.